GERON CORP Revenue, Net (Deprecated 2018-01-31)
GERON CORP (GERN) reported Revenue, Net (Deprecated 2018-01-31) of $462.00 thousand for the 3-month period ending 2011-06-30, per its 10-Q filed 2011-08-05.
Discontinued › Income Statement › Revenue
us-gaap:SalesRevenueNet · last filed 2011-08-05
- GERON CORP revenue, net (deprecated 2018-01-31) for the quarter ending 2011-06-30 was $462.00K, a 53.85% decline year-over-year.
- GERON CORP revenue, net (deprecated 2018-01-31) for the quarter ending 2010-06-30 was $1.00M.
| Period end | Revenue, Net (Deprecated 2018-01-31) 3 month | Revenue, Net (Deprecated 2018-01-31) 6 month |
|---|---|---|
| 2011-06-30 | $462.00K 10-Q · filed 2011-08-05 | $1.97M 10-Q · filed 2011-08-05 |
| 2010-06-30 | $1.00M 10-Q · filed 2011-08-05 | $1.92M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |